Global pharmaceutical policy changes are creating new challenges for biotech companies as they seek to protect asset value and plan international launches. Developments such as US Most-Favored-Nation (MFN) pricing and Europe's Joint Clinical Assessment (JCA) are adding complexity to investment decisions, licensing negotiations and launch planning.
In this webinar, Simon-Kucher experts will examine what these policy developments mean for biotech dealmaking and global launch strategies. We will explore how companies can anticipate policy risks, strengthen their position in discussions with investors and potential partners, and make more informed decisions amid pricing and market access uncertainty.
Participants will learn more about:
- Key pharmaceutical policy developments in 2026 and their implications for pricing, asset valuation and launch strategy
- How policy uncertainty could affect biotech dealmaking, including investor expectations, licensing negotiations and partnership decisions
- Key considerations for global launch planning, including pricing uncertainty, market access challenges and international launch sequencing
By attending this webinar, participants will gain a clearer understanding of how changing pharmaceutical policies could influence biotech asset value, dealmaking and international launch decisions.
